enGene Holdings to Present at Key November Investor Conferences

enGene Holdings ( (ENGN) ) has issued an announcement.

enGene Holdings Inc. announced its participation in several investor conferences in November, including the Guggenheim Annual Healthcare Innovation Conference, Stifel Healthcare Conference, and Jefferies Global Healthcare Conference. These events provide enGene an opportunity to showcase its advancements and engage with potential investors, which could enhance its industry positioning and stakeholder engagement.

The most recent analyst rating on (ENGN) stock is a Buy with a $30.00 price target. To see the full list of analyst forecasts on enGene Holdings stock, see the ENGN Stock Forecast page.

Spark’s Take on ENGN Stock

According to Spark, TipRanks’ AI Analyst, ENGN is a Neutral.

enGene Holdings shows significant financial challenges, with no revenue generation and persistent losses impacting both income and cash flow statements. Technical indicators suggest bearish momentum, with the stock underperforming key moving averages. The valuation is further hampered by a negative P/E ratio and absence of dividends. These factors collectively result in a low overall stock score, highlighting the company’s urgent need to establish a revenue model and improve operational efficiency.

To see Spark’s full report on ENGN stock, click here.

More about enGene Holdings

enGene Holdings Inc. is a clinical-stage biotechnology company focused on developing non-viral genetic medicines. The company specializes in delivering therapeutics to mucosal tissues and other organs, aiming to address diseases with significant clinical needs. Its lead program, detalimogene voraplasmid, targets Non-Muscle Invasive Bladder Cancer and is currently in a Phase 2 trial.

Average Trading Volume: 267,648

Technical Sentiment Signal: Buy

Current Market Cap: $334.3M

See more insights into ENGN stock on TipRanks’ Stock Analysis page.